Polaris Venture Management Co. V, L.L.C. - Q4 2019 holdings

$137 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 11 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .

 Value Shares↓ Weighting
SellPhreesia, Inc.$85,623,000
-1.1%
3,214,092
-10.0%
62.28%
+26.6%
FATE  Fate Therapeutics, Inc.$22,306,000
+26.0%
1,139,7830.0%16.22%
+61.3%
CDLX SellCardlytics, Inc.$12,572,000
-75.1%
200,000
-86.7%
9.14%
-68.2%
SELB  Selecta Biosciences, Inc.$6,650,000
+37.0%
2,773,4790.0%4.84%
+75.4%
XFOR  x4 Pharmaceuticals Inc.$3,333,000
-15.8%
311,4920.0%2.42%
+7.7%
STIM  Neuronetics, Inc.$3,289,000
-46.0%
732,5830.0%2.39%
-30.8%
KALA SellKala Pharmaceuticals, Inc.$2,086,000
-54.2%
565,289
-52.8%
1.52%
-41.4%
LIFE  Atyr Pharma Inc.$544,000
+19.0%
130,5710.0%0.40%
+52.3%
GNCA  Genocea Biosciences, Inc.$509,000
-28.7%
246,0780.0%0.37%
-8.9%
PULM  Pulmatrix, Inc.$309,000
+5.1%
359,4390.0%0.22%
+34.7%
DARE  Dare Bioscience, Inc.$268,000
+5.5%
326,2430.0%0.20%
+35.4%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-02-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings